These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18224510)

  • 21. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
    Shah NT; Miller VA
    Clin Lung Cancer; 2003 Nov; 5(3):182-6. PubMed ID: 14667275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
    Yan DF; Yan SX; Yang JS; Wang YX; Sun XL; Liao XB; Liu JQ
    BMC Cancer; 2010 Feb; 10():49. PubMed ID: 20170543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
    Fujiwara K; Kiura K; Gemba K; Ogata Y; Hotta K; Kishino D; Tabata M; Ueoka H; Tanimoto M
    Anticancer Res; 2005; 25(1B):547-9. PubMed ID: 15816627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
    Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
    Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
    Wataya H; Okamoto T; Maruyama R; Seto T; Yamazaki K; Tagawa T; Fukuyama S; Osoegawa A; Ikeda J; Nishimura M; Yamanaka T; Ichinose Y
    Lung Cancer; 2009 Jun; 64(3):341-5. PubMed ID: 18995926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
    Nakatomi K; Soda H; Kitazaki T; Nakano H; Uchida K; Urabe S; Nakamura Y; Hayashi T; Tsukamoto K; Kohno S
    Lung Cancer; 2006 May; 52(2):253-5. PubMed ID: 16554105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
    Vasile E; Tibaldi C; Chella A; Falcone A
    J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
    Ku GY; Chopra A; Lopes Gde L
    Lung Cancer; 2010 Nov; 70(2):223-5. PubMed ID: 20817304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
    Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
    Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
    Hotta K; Kiura K; Shirahige A; Takata S; Takigawa N; Tabata M; Watanabe H; Tanimoto M
    Acta Oncol; 2009; 48(3):471-3. PubMed ID: 18855159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.